Oppenheimer analyst Steven Lichtman maintained a Buy rating on Mannkind Corp. on Friday, setting a price target of $6.5, which is approximately 46.40% above the present share price of $4.44.
Lichtman expects Mannkind Corp. to post earnings per share (EPS) of -$0.05 for the second quarter of 2021.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in MannKind (NASDAQ:MNKD), with an average price target of $6.1.
The analysts price targets range from a high of $8 to a low of $5.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $17.44 million and a net profit of -$10.03 million. The company's market cap is $1.11 billion.
According to TipRanks.com, Oppenheimer analyst Steven Lichtman is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.9% and a 59.38% success rate.
MannKind Corp . is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.